AMW Appoints Professor Olivia Merkel to the Scientific Advisory Board

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor of Drug Delivery at the Faculty of Chemistry and Pharmacy of Ludwig-Maximilians-Universität (LMU) Munich, as a member of its Scientific Advisory Board (SAB). Prof. Merkel is an internationally recognized expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will strengthen AMW’s scientific expertise in sustained-release delivery systems, such as biodegradable implants, and contribute to the company’s strategic development plans. With her appointment, Prof. Merkel succeeds Prof. Dr. Gerhard Winter, who will step down from his position on the Scientific Advisory Board.

read more

AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.

read more

Further EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.

read more

AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.

read more

AMW Strengthens Management Team to Support the Company’s Growth Strategy

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.

read more

Further marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.

read more